A simple icon, consisting of a series of links surrounded by a circle, is a common symbol for a connection or hyperlink. The lines of the icon are outlined in a dark black color on the background, with the addition of military elements of the Saudi national identity such as the Ghutra, Shamaa, and Saudi Bisht, to reflect the distinctive local character of Qassim University.

Links to official Saudi educational websites end with

edu.sa

All links to official educational websites of government agencies in Saudi Arabia end with .edu.sa.

Black leather minimalist gesture tag, black circular grip, topped with a clear depiction of a Saudi tunic with a shamma and aqal, emphasizing the features of the Saudi bisht. This design symbolizes the concept of security and digital data privacy and reflects the identity of Qassim University.
protocol for encryption and security. HTTPS for encryption and security.
Secure websites in the Kingdom of Saudi Arabia use the HTTPS protocol for encryption.
Digital Government Authority
Registered with the Digital Government Authority with no: 20260416249
Qassim University logo
Open search engine
Search
MyQU Single Sign-On Portal
MyQU

Faculty members

Content

Inside a building, a man dressed in a traditional white uniform with a red and white Saudi shemagh wears a neutral expression as if he were taking a picture of a faculty file at Qassim University.
Photo of the faculty member

abdulrahman Abdullah O Alsuhibani

Assistant Professor
College of Pharmacy,
section

Personal data

  • 00966569988044
  • AA.Alsuhibani@qu.edu.sa
  • Desktop watches
    Google Scholar
    OneDrive

    Scientific qualifications

      Research interests

        Published research

        • Therapeutic drug monitoring of vancomycin: A retrospective cross-sectional study of blood draw timing and clinical outcomes (2025-06-20)
        • Knowledge, Counseling Practice, Perceived Barriers, and Clinical Decision-Making of Community Pharmacists in Saudi Arabia Regarding Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors (2025-01-01)
        • Spending, utilization, and price trends for anti-obesity medications in US Medicaid programs: an empirical analysis from 1999 to 2023 (2025-07-16)
        • Trends in carbapenem antibiotic utilization, costs, and market dynamics in Medicaid: a retrospective analysis from 1991 to 2023 (2025-08-07)
        • Antifungal Agents' Trends of Utilization, Spending, and Prices in the US Medicaid Programs: 2009-2023 (2025-05-16)
        • Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA Adverse Event Reporting System (FAERS) databases 2013-2020 (2021-09-26)
        • Factors Associated with Statin Discontinuation Following Metabolic and Bariatric Surgery: A Retrospective Analysis of 2012-2021 Electronic Medical Records Network Data (2024-02-22)
        • A risk stratification analysis of atherosclerotic cardiovascular disease events post-statin discontinuation in patients who underwent sleeve gastrectomy or Roux-en-Y gastric bypass bariatric/metabolic surgeries (2024-08-15)
        • Drug Expenditure, Price, and Utilization in US Medicaid: A Trend Analysis for New Multiple Myeloma Medications from 2016 to 2022 (2023-08-01)
        • Descriptive Analysis of Adverse Events Reported for New Multiple Myeloma Medications Using FDA Adverse Event Reporting System (FAERS) Databases from 2015 to 2022 (2024-07-01)
        • Cost-utility of first-line dostarlimab plus carboplatin-paclitaxel compared with placebo for patients with pA/rEC: a partitioned survival analysis (2026-04-23)
        • Analyzing the direct medical cost of schizophrenia in Penang Hospital, Malaysia (2026-05-16)
        • Inappropriate medication use and associated factors in geriatric patients with hypertension and diabetes (2026-04-01)
        • Spending, Utilization, and Price Trends for Anti-Obesity Medications in US Medicaid Programs: A Comprehensive Analysis from 1999 to 2023 (2025-08-01)
        • HEALTH HALO EFFECT IN SUPPLEMENT MARKETING: A CONTENT ANALYSIS OF MEDICAL CLAIMS IN COMMUNITY PHARMACIES (2025-12-01)
        • Gender Disparities in Quality of Life Among Chronic Liver Disease Patients: A Meta-Analysis (2025-04-01)
        • Cost-Effectiveness Analysis of Ofatumumab versus Teriflunomide for Relapsing-Remitting Multiple Sclerosis: A 10-Year Markov Model (2025-01-01)
        • Pharmacy students' interprofessional experience and performance in advanced pharmacy practice experience rotations amid the COVID-19 pandemic (2024-05-21)
        • Utilization, reimbursement, and price trends for Hepatitis C virus medications in US Medicaid programs: 2001-2021 (2023-12-05)
        • Trends in anti-obesity drugs utilization, spending, and prices in Medicaid programs: 1999-2021 (2023-10-01)
        • Psychological and neurological adverse drug events associated with direct-acting antiviral agents used for hepatitis C virus: analysis and comparison of the FDA Adverse Event Reporting System (FAERS) and Lexicomp (2023-10-01)
        • Bariatric surgery utilization trends in the United States: 2012-2021 (2023-10-01)
        • Comparison of quality of life between men and women with chronic liver diseases using the Chronic Liver Disease Questionnaire (CLDQ): A meta-analysis (2021-08-01)
        • Evaluation of Statin Discontinuation Stratified by Primary Versus Secondary Prevention Following Bariatric Surgery: A Retrospective Cohort Study (2021-08-01)
        • Safety evaluation of panobinostat, ixazomib, elotuzumab, and daratumumab using FDA Adverse Event Reporting System (FAERS) database 2015-2020 (2021-08-01)
        • Bariatric Surgery Utilization Trends in the United States Following COVID-19 and the 2022 ASMBS/IFSO Guideline Expansion: An Interrupted Time Series Analysis (2026-06-13)
        • Metabolic and bariatric surgery utilization trends in the United States: evidence from 2012 to 2021 national electronic medical records network (2023-01-01)
        • Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA Adverse Event Reporting System (FAERS) databases 2013–2020 (2022-01-01)
        • Evaluation of statin discontinuation stratified by primary versus secondary prevention following bariatric surgery: a retrospective cohort study (2021-01-01)
        • Antifungal Agents’ Trends of Utilization, Spending, and Prices in the US Medicaid Programs: 2009–2023 (2025-01-01)
        • Cost-effectiveness analysis of ofatumumab versus teriflunomide for relapsing-remitting multiple sclerosis: a 10-year Markov model (2025-01-01)
        • Spending, utilization, and price trends for anti-obesity medications in US Medicaid programs: an empirical analysis from 1999 to 2023 (2025-01-01)
        • Knowledge, counseling practice, perceived barriers, and clinical decision-making of community pharmacists in Saudi Arabia regarding glucagon-like peptide-1 receptor agonists … (2025-01-01)
        • Therapeutic drug monitoring of vancomycin: A retrospective cross-sectional study of blood draw timing and clinical outcomes (2025-01-01)
        • Changes in utilization of immediate-release, extended-release, and liquid formulation medications relative to bariatric surgery: a segmented regression analysis (2021-01-01)
        • Descriptive analysis of adverse events reported for new multiple myeloma medications using FDA adverse event reporting system (FAERS) databases from 2015 to 2022 (2024-01-01)
        • Utilization, reimbursement, and price trends for hepatitis C virus medications in the US medicaid programs: 2001–2021 (2023-01-01)
        • A risk stratification analysis of atherosclerotic cardiovascular disease events post-statin discontinuation in patients who underwent sleeve gastrectomy or Roux-en-Y gastric ... (2024-01-01)
        • Factors associated with statin discontinuation following metabolic and bariatric surgery: a retrospective analysis of 2012–2021 electronic medical records network data (2024-01-01)
        • Cost-utility of first-line dostarlimab plus carboplatin-paclitaxel compared with placebo for patients with pA/rEC: a partitioned survival analysis (2026-01-01)
        • Safety evaluation of panobinostat, ixazomib, elotuzumab, and daratumumab using FDA Adverse Event Reporting System (FAERS) database 2015-2020 (2021-01-01)
        • Comparison of quality of life between men and women with chronic liver diseases using the Chronic Liver Disease Questionnaire (CLDQ): A meta-analysis (2021-01-01)
        • Bariatric Surgery Utilization Trends in the United States Following COVID-19 and the 2022 ASMBS/IFSO Guideline Expansion: An Interrupted Time Series Analysis (2026-01-01)
        • Analyzing the direct medical cost of schizophrenia in Penang Hospital, Malaysia (2026-01-01)
        • Inappropriate medication use and associated factors in geriatric patients with hypertension and diabetes (2026-01-01)
        • Pharmaceutical Services for Visually Impaired Patients: Views and Challenges Perceived by Pharmacists and Patients in the Qassim Region of Saudi Arabia (2026-01-01)
        • HPR112 Health Halo Effect in Supplement Marketing: A Content Analysis of Medical Claims in Community Pharmacies (2025-01-01)
        • Trends in carbapenem antibiotic utilization, costs, and market dynamics in Medicaid: a retrospective analysis from 1991 to 2023 (2025-01-01)
        • Gender Disparities in Quality of Life Among Chronic Liver Disease Patients: A Meta-Analysis (2025-01-01)
        • A risk stratification analysis of ASCVD events post-statin discontinuation in patients who underwent sleeve gastrectomy or Roux-en-Y gastric bypass bariatric/metabolic surgeries. (2024-01-01)
        • EPH160 A Risk Stratification Analysis of ASCVD Events Post-Statin Discontinuation in Bariatric Surgery Patients (2024-01-01)
        • Pharmacy students’ interprofessional experience and performance in advanced pharmacy practice experience rotations amid COVID-19 pandemic (2024-01-01)
        • Psychological and neurological adverse drug events associated with direct acting antivirals agents used for hepatitis C virus: Analysis and comparison of the FDA adverse event … (2023-01-01)
        • Trends in anti-obesity drugs utilization, spending, and prices in Medicaid programs: 1999-2021 (2023-01-01)
        • Bariatric surgery utilization trends in the United States: 2012-2021 (2023-01-01)
        • Drug Expenditure, Price, and Utilization in US Medicaid: A Trend Analysis for New Multiple Myeloma Medications from 2016 to 2022 (2023-01-01)
        • EPH57 Trends in Utilization, Spending, and Prices of Anti-Obesity Medications in Medicaid Programs: 22 Years Empirical Data Analysis, 1999-2021 (2023-01-01)
        • EE20 Utilization, Reimbursements and Prices Trends of Hepatitis C Virus Drugs in the US Medicaid Programs from 2001 to 2021 (2023-01-01)
        • CO189 Metabolic and Bariatric Surgery Utilization Trends in the United States: Evidence from 2012–2021 National Electronic Medical Records Data (2023-01-01)
        • Metabolic and Bariatric Surgery: Utilization, Statin Discontinuation, and Cardiovascular Risk Stratification in the Modern Era (2023-01-01)
        • School Poster Abstracts Presented at the 123rd Annual Meeting of the American Association of Colleges of Pharmacy, July 23-27, 2022 (2022-01-01)
        • Antifungal Agents’ Trends of Utilization, Spending, and Prices in the US Medicaid Programs: 2009–2023. Antibiotics 2025, 14, 518. htps (2026-01-01)

        Teaching materials

          Suggestions

          Single Sign-On Portal
          Achievement
          E-learning
          Email
          Directory of services
          Query services

          Cookies

          This website uses special cookies to ensure ease of use, improve your browsing experience, and clarify the terms and policies related to About user privacy. By continuing to browse this website, you acknowledge that you accept the use of cookies and the terms of the Privacy Policy

          Accept